Tecentriq 1200 Injection

Tecentriq 1200 Injection is an anti-cancer medicine used in the treatment of unresectable, stage II-IIIa non-small cell lung cancer (NSCLC). Tecentriq 1200 Injection is also used in combination with other cancer medicine for the treatment of metastatic NSCLC (bevacizumab, paclitaxel, carboplatin), extensive-stage small cell lung cancer and biliary tract cancer (carboplatin, etoposide), metastatic melanoma (cobimetinib, vemurafenib), and unresectable hepatocellular cancer (bevacizumab).

Tecentriq 1200 Injection contains Atezolizumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1), thereby stopping the abnormal growth of cancer cells.

Tecentriq 1200 Injection may cause certain side effects such as fatigue, cough, diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, shortness of breath, muscle/joint pain, abdominal pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for longer. Tecentriq 1200 Injection will be administered by an oncologist trained in administering anti-cancer agents. 

Avoid receiving Tecentriq 1200 Injection and inform your doctor if you are allergic to it or any other components of it. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. Avoid breastfeeding while taking this Tecentriq 1200 Injection. Before starting treatment with Tecentriq 1200 Injection, tell your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis or Crohn's disease, a history of organ transplants, received an allogeneic stem cell transplant, or had radiation treatment to the chest, and myasthenia gravis.

Tecentriq 1200 Injection contains Atezolizumab, which is used in the treatment of different types of cancers. It works by inhibiting the action of a programmed death ligand receptor-1 (PD-L1) that causes the multiplication of cancer cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other body parts.

To treat your condition effectually, continue receiving Tecentriq 1200 Injection for the period that your doctor has prescribed. Tecentriq 1200 Injection may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, hepatotoxicity, nephritis, endocrinopathies, pneumonitis, cardiac problems, and dermatologic reactions. It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders, autoimmune disorders such as ulcerative colitis or Crohn’s disease, lung disease, heart problems, and breathing difficulty while receiving Tecentriq 1200 Injection. This medicine may also cause severe infusion-related reactions. Hence, careful monitoring is recommended and discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established.

• Your doctor may suggest periodic liver function tests, kidney function tests, and lung function tests to monitor the function of the liver, kidney and lungs due to the use of Tecentriq 1200 Injection.
• Using contraceptive pills while using Tecentriq 1200 Injection to prevent pregnancy is advised.
• Thyroid function and adrenocorticotropic hormone levels will be monitored during treatment to avoid any life-threatening side effects.